Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases
Pediatric Allergy and Immunology2016Vol. 27(5), pp. 493–498
Citations Over TimeTop 10% of 2016 papers
Zoltán Novàk, Anahí Yáñez, I Kiss, Piotr Kuna, Miguel Tortajada‐Girbés, Román Valiente, the “Bilastine Paediatric Safety Study Group”
Abstract
Bilastine 10 mg had a safety and tolerability profile similar to that of placebo in children aged 2 to <12 years with allergic rhinoconjunctivitis or chronic urticaria.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study(1999)81 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Types Research of Discontinuation of a Crime(2007)